Jason Amello - 01 Feb 2024 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Financial Officer
Signature
/s/ Zoran Zdraveski, Attorney-in-Fact
Issuer symbol
TCRX
Transactions as of
01 Feb 2024
Transactions value $
$0
Form type
4
Filing time
02 Feb 2024, 16:21:56 UTC
Previous filing
02 Feb 2024
Next filing
11 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +750K $0.00 750K 01 Feb 2024 Voting Common Stock 750K $5.15 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of January 29, 2024, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer.